Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

4.5%

5 terminated/withdrawn out of 111 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

14%

15 trials in Phase 3/4

Results Transparency

13%

2 of 15 completed trials have results

Key Signals

36 recruiting2 with results5 withdrawn

Enrollment Performance

Analytics

N/A

42(51.2%)

Phase 1

12(14.6%)

Phase 3

9(11.0%)

Early Phase 1

8(9.8%)

Phase 4

6(7.3%)

Phase 2

5(6.1%)

82Total

N/A(42)

Phase 1(12)

Phase 3(9)

Early Phase 1(8)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (111)

Showing 20 of 111 trials

NCT06772402Not ApplicableEnrolling By Invitation

GCB-001 in Treatment of Patients With Type II (SMA) Spinal Muscular Atrophy

Role: collaborator

NCT07813208Recruiting

Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival

Role: lead

NCT06792344Phase 1Suspended

Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis

Role: lead

NCT07183878Not ApplicableRecruiting

Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)

Role: collaborator

NCT07003737Not ApplicableRecruiting

Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT07347990Not ApplicableRecruiting

Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy

Role: collaborator

NCT07184853Not ApplicableRecruiting

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Role: collaborator

NCT06890143Phase 3Recruiting

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children

Role: collaborator

NCT07674147Early Phase 1Not Yet Recruiting

RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases

Role: lead

NCT06842589Phase 1Withdrawn

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

Role: lead

NCT06508346Withdrawn

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

Role: lead

NCT06525116Completed

MRD Detection by NGS in Pediatric T-ALL

Role: lead

NCT07450872Recruiting

Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors

Role: lead

NCT07615803Not Yet Recruiting

Study on Influencing Factors of Skin Complications Related to Insulin Injection in Children With Type 1 Diabetes Mellitus

Role: lead

NCT07595939Phase 3Not Yet Recruiting

Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo

Role: lead

NCT07593118Not ApplicableNot Yet Recruiting

Exergame-Based Physical Activity Promotion for Children and Adolescents With Congenital Heart Disease

Role: lead

NCT07335991Not ApplicableRecruiting

Effect of Vitamin A Supplementation on Idiopathic Scoliosis

Role: collaborator

NCT07332780Not ApplicableRecruiting

Effect of Adenotonsillectomy on Spinal Curve Magnitude in Children With Sleep-Disordered Breathing

Role: collaborator

NCT07586267Early Phase 1Recruiting

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

Role: lead

NCT07574463Not ApplicableNot Yet Recruiting

Adaptive Digital Exercise Rehabilitation for Children After CHD Surgery

Role: lead